Skip to main content

Table 4 Comparison of the groups on the basis of renal functions and acute phase parameters

From: Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever

  All group(n = 12) AA + FMF(n = 8) AA + FMF + co-existing diseases(n = 4)
Before treatment After treatment Before treatment After treatment Before treatment After treatment
Creatinine (mg/dl) (Female: 0.5–0.9; Male:0.7–1.2) 1.1 ± 0.9 1.0 ± 0.6 1.2 ± 1.1 1.0 ± 0.7 0.9 ± 0.4 1.0 ± 0.4
GFR (ml/min) (71–151) 111.7 ± 50.1 108.9 ± 54.8 118.1 ± 59.4 122.1 ± 62.8 99.0 ± 25.5 82.7 ± 20.4
Proteinuria (mg/day) 6537.6 ± 6526.0 4745.5 ± 5462.7 7920.1 ± 7576.9 5417.9 ± 6585.0 3772.6 ± 2628.7 3400.6 ± 2149.8
CRP (0–5 mg/L) 18.1 ± 19.5 5.8 ± 7.1 20.5 ± 23.3 4.1 ± 5.2 13.3 ± 9.0 9.3 ± 10.0
Sedimentation (0–20 mm/h) 48.7 ± 31.0 27.8 ± 28.3 54.9 ± 34.2 24.0 ± 22.4 36.3 ± 22.0 35.5 ± 40.5